FindTrial
Sign In

Development of CSF/plasma biomarker which can predict onset of Alzheimer's disease

Development of CSF/plasma biomarker which can predict onset of Alzheimer's disease - Development of Alzheimer's disease biomarker

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000025008
Enrollment
1000
Registered
2016-12-12
Start date
2008-02-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer&#39

Interventions

AD or MCI patients in neuropsychiatry department in Osaka University are recruited. They undergo cognition tests including MMSE and CSF and/or blood sampling. Non-AD patients in neuropsychiatry depart

Sponsors

Osaka University
Lead Sponsor
J-ADNI Osaka University Mental Health Promotion Higashi Matsudo Hospital Dept. of Mol. Genetics, Brain Res. Institute, Niigata Univ
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who are clinically diagnosed as Alzheimer`s Disease, MCI, or non-AD.

Exclusion criteria

Exclusion criteria: not particular

Design outcomes

Primary

MeasureTime frame
We investigate how the value or the ratio of Abeta like peptides change in CSF or plasma of AD, MCI, or preclinical AD patients.—

Countries

Japan

Contacts

Public ContactMasayasu Okochi

Osaka University Graduate School of Medicine Department of Neuropsychiatry

mokochi@psy.med.osaka-u.ac.jp06-6879-3051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026